Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL27893486 | 0.97 | ALDH1A1 (0.39) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL4217278 | 0.82 | ALDH1A1 (0.33) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL16074875 | 0.76 | TSHR (0.39) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL29222592 | 0.74 | — | — | |
| SCHEMBL11149133 | 0.74 | — | — | |
| SCHEMBL26102924 | 0.73 | FDPS (0.42) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL506048 | 0.71 | — | — | |
| SCHEMBL1236770 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL410636 | 0.71 | — | — | |
| SCHEMBL10685286 | 0.69 | FDPS (0.39) | ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-10364218-B2 | Method of producing epsilon-caprolactam | TORAY INDUSTRIES, INC. (JP) | 2019-07-30 | — | — | US | disclosed |
| US-20180237389-A1 | METHOD OF PRODUCING EPSILON-CAPROLACTAM | TORAY INDUSTRIES, INC. (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-3348544-A1 | METHOD FOR PRODUCING -CAPROLACTAM | Toray Industries, Inc. (JP) | 2018-07-18 | — | — | EP | disclosed |
| CN-108026048-A | The manufacture method of epsilon-caprolactams | 东丽株式会社 | 2018-05-11 | — | — | CN | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013062133-A1 | PATTERN FORMING METHOD, MULTI-LAYERED RESIST PATTERN, MULTI-LAYERED FILM FOR ORGANIC SOLVENT DEVELOPMENT, MANUFACTURING METHOD OF ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2013-05-02 | — | — | WO | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-0463479-B1 | Preparation of cellular synthetic resins by the polyisocyanate polyaddition process using tertiary alcohols | BASF AG (DE) | 1999-01-13 | — | — | EP | disclosed |
| US-5189068-A | Forming polyurethanes and polyisocyanurates; chain extension, blowing, catalytic | BASF AKTIENGESELLSCHAFT (DE) | 1993-02-23 | — | — | US | disclosed |
| EP-0463479-A2 | Preparation of cellular synthetic resins by the polyisocyanate polyaddition process using tertiary alcohols | BASF Aktiengesellschaft (DE) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364218-B2 | Method of producing epsilon-caprolactam | CAPRIN1, PTMA, CYP51A1 | ALDH1A1 584/4885CYP2C19 1948/4885TSHR 4633/4885 |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ALDH1A1 1149/4885CYP2C19 794/4885TSHR 740/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | ALDH1A1 309/4885CYP2C19 281/4885TSHR 2380/4885 |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | ALDH1A1 1173/4885CYP2C19 1613/4885TSHR 1166/4885 |
| US-20180237389-A1 | METHOD OF PRODUCING EPSILON-CAPROLACTAM | CAPRIN1, PTMA, CYP51A1 | ALDH1A1 584/4885CYP2C19 1948/4885TSHR 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.